Published in Semin Immunol on October 01, 2004
Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev (2009) 3.61
Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. J Exp Med (2008) 3.15
Public clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV infection. J Exp Med (2009) 2.03
Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev (2006) 1.81
Preferential infection shortens the life span of human immunodeficiency virus-specific CD4+ T cells in vivo. J Virol (2006) 1.68
Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity. J Clin Invest (2006) 1.64
Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. J Virol (2006) 1.54
Cross-reactivity of T lymphocytes recognizing a human cytotoxic T-lymphocyte epitope within BK and JC virus VP1 polypeptides. J Virol (2005) 1.26
CD8 T cell cross-reactivity networks mediate heterologous immunity in human EBV and murine vaccinia virus infections. J Immunol (2010) 1.05
The narrowing of the CD8 T cell repertoire in old age. Curr Opin Immunol (2011) 1.04
Protection against vaccinia virus challenge by CD8 memory T cells resolved by molecular mimicry. J Virol (2006) 1.01
Broad cross-reactive TCR repertoires recognizing dissimilar Epstein-Barr and influenza A virus epitopes. J Immunol (2010) 1.00
Heterologous immunity: immunopathology, autoimmunity and protection during viral infections. Autoimmunity (2011) 0.98
A discrete computer model of the immune system reveals competitive interactions between the humoral and cellular branch and between cross-reacting memory and naïve responses. Vaccine (2008) 0.96
Studies in the modulation of experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol (2010) 0.95
Clonal expansion and TCR-independent differentiation shape the HIV-specific CD8+ effector-memory T-cell repertoire in vivo. Blood (2010) 0.92
Experimental autoimmune encephalomyelitis as a testing paradigm for adjuvants and vaccines. Vaccine (2010) 0.91
Every breath you take: the impact of environment on resident memory CD8 T cells in the lung. Front Immunol (2014) 0.90
Memory T Cell Migration. Front Immunol (2015) 0.87
Narrowing of human influenza A virus-specific T cell receptor α and β repertoires with increasing age. J Virol (2015) 0.86
Disparate epitopes mediating protective heterologous immunity to unrelated viruses share peptide-MHC structural features recognized by cross-reactive T cells. J Immunol (2013) 0.86
Endogenous memory CD8 T cells directly mediate cardiac allograft rejection. Am J Transplant (2014) 0.83
Degeneracy-driven self-structuring dynamics in selective repertoires. Bull Math Biol (2009) 0.83
Human leukocyte antigens A*3001 and A*3002 show distinct peptide-binding patterns of the Mycobacterium tuberculosis protein TB10.4: consequences for immune recognition. Clin Vaccine Immunol (2010) 0.81
H. pylori-infection and antibody immune response in a rural Tanzanian population. Infect Agent Cancer (2006) 0.81
Memory T Cells in Transplantation. Curr Transplant Rep (2014) 0.81
The two faces of heterologous immunity: protection or immunopathology. J Leukoc Biol (2013) 0.80
CrossTope: a curate repository of 3D structures of immunogenic peptide: MHC complexes. Database (Oxford) (2013) 0.79
Viral infection in renal transplant recipients. ScientificWorldJournal (2012) 0.79
CD4(+) and CD8(+) T-cell immunity to Dengue - lessons for the study of Zika virus. Immunology (2016) 0.78
Individual MHCI-Restricted T-Cell Receptors are Characterized by a Unique Peptide Recognition Signature. Front Immunol (2013) 0.78
Sequential immunization with heterologous chimeric flaviviruses induces broad-spectrum cross-reactive CD8+ T cell responses. J Infect Dis (2010) 0.77
Disruption of Transplant Tolerance by an 'Incognito' Form of CD8(+) T Cell-Dependent Memory. Am J Transplant (2017) 0.75
Computer simulations of heterologous immunity: highlights of an interdisciplinary cooperation. Autoimmunity (2011) 0.75
Differences in TCR-Vβ repertoire and effector phenotype between tumor infiltrating lymphocytes and peripheral blood lymphocytes increase with age. PLoS One (2014) 0.75
Viral infection: a potent barrier to transplantation tolerance. Clin Dev Immunol (2008) 0.75
Vaccination and heterologous immunity: educating the immune system. Trans R Soc Trop Med Hyg (2015) 0.75
A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma. Oncoimmunology (2017) 0.75
Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol (2012) 3.41
Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology (2006) 3.18
Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. Nano Lett (2008) 2.98
Memory of mice and men: CD8+ T-cell cross-reactivity and heterologous immunity. Immunol Rev (2006) 2.79
Natural killer cells act as rheostats modulating antiviral T cells. Nature (2011) 2.68
Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol (2010) 2.58
T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens. Nat Immunol (2002) 2.21
Heterologous immunity between viruses. Immunol Rev (2010) 2.20
Specific history of heterologous virus infections determines anti-viral immunity and immunopathology in the lung. Am J Pathol (2003) 2.05
Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. Hepatology (2012) 1.94
Cutting edge: MHC class II-restricted killing in vivo during viral infection. J Immunol (2005) 1.93
Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptides in vivo and plays an important role in immunodominance. Proc Natl Acad Sci U S A (2006) 1.91
Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One (2013) 1.89
Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol (2011) 1.86
Private specificities of CD8 T cell responses control patterns of heterologous immunity. J Exp Med (2005) 1.85
Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology (2010) 1.85
Virus-specific CD8 T cells in peripheral tissues are more resistant to apoptosis than those in lymphoid organs. Immunity (2003) 1.85
SITEHOUND-web: a server for ligand binding site identification in protein structures. Nucleic Acids Res (2009) 1.82
Cross-reactive influenza virus-specific CD8+ T cells contribute to lymphoproliferation in Epstein-Barr virus-associated infectious mononucleosis. J Clin Invest (2005) 1.76
Polyspecificity of T cell and B cell receptor recognition. Semin Immunol (2007) 1.68
Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity. J Clin Invest (2006) 1.64
Direct visualization of cross-reactive effector and memory allo-specific CD8 T cells generated in response to viral infections. J Immunol (2003) 1.61
Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis (2013) 1.58
TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts. J Immunol (2006) 1.57
Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. J Hepatol (2011) 1.55
IFN-induced attrition of CD8 T cells in the presence or absence of cognate antigen during the early stages of viral infections. J Immunol (2006) 1.54
Plasticity of T cell memory responses to viruses. Immunity (2004) 1.53
Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J Clin Invest (2005) 1.50
Absence of mouse 2B4 promotes NK cell-mediated killing of activated CD8+ T cells, leading to prolonged viral persistence and altered pathogenesis. J Clin Invest (2010) 1.47
Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging. JACC Cardiovasc Imaging (2011) 1.46
Mice completely lacking immunoproteasomes show major changes in antigen presentation. Nat Immunol (2011) 1.45
Humanized nonobese diabetic-scid IL2rgammanull mice are susceptible to lethal Salmonella Typhi infection. Proc Natl Acad Sci U S A (2010) 1.41
Role for TLR2 in NK cell-mediated control of murine cytomegalovirus in vivo. J Virol (2006) 1.35
Dynamics of memory T cell proliferation under conditions of heterologous immunity and bystander stimulation. J Immunol (2002) 1.35
Type 1 IFN mediates cross-talk between innate and adaptive immunity that abrogates transplantation tolerance. J Immunol (2007) 1.34
Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. Mol Pharm (2010) 1.28
Antigen dependent and independent mechanisms that sustain serum antibody levels. Vaccine (2003) 1.27
Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl (2010) 1.26
MyD88 is required for the formation of long-term humoral immunity to virus infection. J Immunol (2007) 1.24
Multifunctional nanoemulsion platform for imaging guided therapy evaluated in experimental cancer. ACS Nano (2011) 1.23
c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood (2014) 1.23
Rapid production of TNF-alpha following TCR engagement of naive CD8 T cells. J Immunol (2005) 1.19
Dual function of the NK cell receptor 2B4 (CD244) in the regulation of HCV-specific CD8+ T cells. PLoS Pathog (2011) 1.17
Comprehensive early and lasting loss of memory CD8 T cells and functional memory during acute and persistent viral infections. J Immunol (2004) 1.17
Programmed death-1 (PD-1) defines a transient and dysfunctional oligoclonal T cell population in acute homeostatic proliferation. J Exp Med (2007) 1.17
Virus-induced transient immune suppression and the inhibition of T cell proliferation by type I interferon. J Virol (2011) 1.16
IFN-alpha beta and self-MHC divert CD8 T cells into a distinct differentiation pathway characterized by rapid acquisition of effector functions. J Immunol (2010) 1.14
Enhanced humoral and HLA-A2-restricted dengue virus-specific T-cell responses in humanized BLT NSG mice. Immunology (2012) 1.12
Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology (2004) 1.12
Biochemical and functional analysis of smallpox growth factor (SPGF) and anti-SPGF monoclonal antibodies. J Biol Chem (2004) 1.11
CD8 T cell responses to viral infections in sequence. Cell Microbiol (2004) 1.10
Tec kinases Itk and Rlk are required for CD8+ T cell responses to virus infection independent of their role in CD4+ T cell help. J Immunol (2006) 1.10
Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells. J Virol (2007) 1.09
Maturation-dependent licensing of naive T cells for rapid TNF production. PLoS One (2010) 1.09
Dynamic glucoregulation and mammalian-like responses to metabolic and developmental disruption in zebrafish. Gen Comp Endocrinol (2010) 1.07
A fluorescent, paramagnetic and PEGylated gold/silica nanoparticle for MRI, CT and fluorescence imaging. Contrast Media Mol Imaging (2010) 1.07
Analysis of apoptosis of memory T cells and dendritic cells during the early stages of viral infection or exposure to toll-like receptor agonists. J Virol (2010) 1.07
Comparison of synthetic high density lipoprotein (HDL) contrast agents for MR imaging of atherosclerosis. Bioconjug Chem (2009) 1.05
Infections that induce autoimmune diabetes in BBDR rats modulate CD4+CD25+ T cell populations. J Immunol (2003) 1.05
CD8 T cell cross-reactivity networks mediate heterologous immunity in human EBV and murine vaccinia virus infections. J Immunol (2010) 1.05
Humanized mice as a preclinical tool for infectious disease and biomedical research. Ann N Y Acad Sci (2011) 1.04
Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology (2014) 1.04
Protection against vaccinia virus challenge by CD8 memory T cells resolved by molecular mimicry. J Virol (2006) 1.01
Prevalence and risk factors of carotid vessel wall inflammation in coronary artery disease patients: FDG-PET and CT imaging study. JACC Cardiovasc Imaging (2011) 1.01
Imaging the efficacy of anti-inflammatory liposomes in a rabbit model of atherosclerosis by non-invasive imaging. Methods Enzymol (2012) 1.01
Broad cross-reactive TCR repertoires recognizing dissimilar Epstein-Barr and influenza A virus epitopes. J Immunol (2010) 1.00
CD4 T-cell-mediated heterologous immunity between mycobacteria and poxviruses. J Virol (2009) 1.00
Regression of inflammation in atherosclerosis by the LXR agonist R211945: a noninvasive assessment and comparison with atorvastatin. JACC Cardiovasc Imaging (2012) 1.00
Loss of anti-viral immunity by infection with a virus encoding a cross-reactive pathogenic epitope. PLoS Pathog (2012) 0.99